Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 2
2006 1
2007 2
2008 6
2009 4
2010 1
2011 7
2012 7
2013 5
2014 7
2015 9
2016 16
2017 13
2018 5
2019 19
2020 25
2021 14
2022 14
2023 14
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

153 results

Results by year

Filters applied: . Clear all
Page 1
Safety and preliminary efficacy of pembrolizumab following trans-arterial chemoembolization for hepatocellular carcinoma: the PETAL phase Ib study.
Pinato DJ, D'Alessio A, Fulgenzi CAM, Schlaak AE, Celsa C, Killmer S, Blanco JM, Ward C, Stikas CV, Openshaw MR, Acuti N, Nteliopoulos G, Balcells C, Keun HC, Goldin RD, Ross PJ, Cortellini A, Thomas R, Young AM, Danckert N, Tait P, Marchesi JR, Bengsch B, Sharma R. Pinato DJ, et al. Among authors: sharma r. Clin Cancer Res. 2024 Apr 5. doi: 10.1158/1078-0432.CCR-24-0177. Online ahead of print. Clin Cancer Res. 2024. PMID: 38578610
Somatostatin Receptor Imaging with [18F]FET-βAG-TOCA PET/CT and [68Ga]Ga-DOTA-Peptide PET/CT in Patients with Neuroendocrine Tumors: A Prospective, Phase 2 Comparative Study.
Dubash S, Barwick TD, Kozlowski K, Rockall AG, Khan S, Khan S, Yusuf S, Lamarca A, Valle JW, Hubner RA, McNamara MG, Frilling A, Tan T, Wernig F, Todd J, Meeran K, Pratap B, Azeem S, Huiban M, Keat N, Lozano-Kuehne JP, Aboagye EO, Sharma R. Dubash S, et al. Among authors: sharma r. J Nucl Med. 2024 Feb 8;65(3):416-22. doi: 10.2967/jnumed.123.266601. Online ahead of print. J Nucl Med. 2024. PMID: 38331457 Free PMC article.
Corrigendum: Sorafenib increases cytochrome P450 lipid metabolites in patient with hepatocellular carcinoma.
Leineweber CG, Rabehl M, Pietzner A, Rohwer N, Rothe M, Pech M, Sangro B, Sharma R, Verslype C, Basu B, Sengel C, Ricke J, Schebb NH, Weylandt KH, Benckert J. Leineweber CG, et al. Among authors: sharma r. Front Pharmacol. 2024 Jan 11;14:1354581. doi: 10.3389/fphar.2023.1354581. eCollection 2023. Front Pharmacol. 2024. PMID: 38273836 Free PMC article.
Study protocol of LANTana: a phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours, UK.
Murphy R, Chander G, Martinez M, Ward C, Khan SR, Naik M, Barwick T, Aboagye E, Sharma R. Murphy R, et al. Among authors: sharma r. BMJ Open. 2023 Oct 24;13(10):e075221. doi: 10.1136/bmjopen-2023-075221. BMJ Open. 2023. PMID: 37879695 Free PMC article.
Impact of COVID-19 on 1-Year Survival Outcomes in Hepatocellular Carcinoma: A Multicenter Cohort Study.
De Souza S, Kahol de Jong J, Perone Y, Shetty S, Qurashi M, Vithayathil M, Shah T, Ross P, Temperley L, Yip VS, Banerjee A, Bettinger D, Sturm L, Reeves HL, Geh D, Orr J, Allen B, Jones RP, Sharma R. De Souza S, et al. Among authors: sharma r. Cancers (Basel). 2023 Jun 27;15(13):3378. doi: 10.3390/cancers15133378. Cancers (Basel). 2023. PMID: 37444488 Free PMC article.
NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma.
McNamara MG, Swain J, Craig Z, Sharma R, Faluyi O, Wadsley J, Morgan C, Wall LR, Chau I, Reed N, Sarker D, Margetts J, Krell D, Cave J, Sothi S, Anthoney A, Bell C, Patel A, Oughton JB, Cairns DA, Mansoor W, Lamarca A, Hubner RA, Valle JW. McNamara MG, et al. Among authors: sharma r. EClinicalMedicine. 2023 Jun 2;60:102015. doi: 10.1016/j.eclinm.2023.102015. eCollection 2023 Jun. EClinicalMedicine. 2023. PMID: 37287870 Free PMC article.
Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma.
Vithayathil M, D'Alessio A, Fulgenzi CAM, Nishida N, Schönlein M, von Felden J, Schulze K, Wege H, Saeed A, Wietharn B, Hildebrand H, Wu L, Ang C, Marron TU, Weinmann A, Galle PR, Bettinger D, Bengsch B, Vogel A, Balcar L, Scheiner B, Lee PC, Huang YH, Amara S, Muzaffar M, Naqash AR, Cammarota A, Zanuso V, Pressiani T, Pinter M, Cortellini A, Kudo M, Rimassa L, Pinato DJ, Sharma R. Vithayathil M, et al. Among authors: sharma r. Hepatol Int. 2023 Aug;17(4):904-914. doi: 10.1007/s12072-023-10491-3. Epub 2023 Apr 1. Hepatol Int. 2023. PMID: 37005953 Free PMC article.
153 results